Opioid coprescription through risk mitigation guidance and opioid agonist treatment receipt

Simple item page
dc.contributor.authorMin, Jeong Eun
dc.contributor.authorGuerra-Alejos, Brenda Carolina
dc.contributor.authorYan, Ruyu
dc.contributor.authorPalis, Heather
dc.contributor.authorBarker, Brittany
dc.contributor.authorUrbanoski, Karen
dc.contributor.authorPauly, Bernie
dc.contributor.authorSlaunwhite, Amanda
dc.contributor.authorBach, Paxton
dc.contributor.authorRanger, Corey
dc.contributor.authorHeaslip, Ashley
dc.contributor.authorNosyk, Bohdan
dc.date.accessioned2025-03-18T16:02:05Z
dc.date.available2025-03-18T16:02:05Z
dc.date.issued2024
dc.description.abstractAt the onset of the COVID-19 pandemic, the government of British Columbia, Canada, released clinical guidance to support physicians and nurse practitioners in prescribing pharmaceutical alternatives to the toxic drug supply. These alternatives included opioids and other medications under the risk mitigation guidance (RMG), a limited form of prescribed safer supply, designed to reduce the risk of SARS-CoV-2 infection and harms associated with illicit drug use. Many clinicians chose to coprescribe opioid medications under RMG alongside opioid agonist treatment (OAT).To examine whether prescription of hydromorphone tablets or sustained-release oral morphine (opioid RMG) and OAT coprescription compared with OAT alone is associated with subsequent OAT receipt.This population-based, retrospective cohort study was conducted from March 27, 2020, to August 31, 2021, included individuals from 10 linked health administrative databases from British Columbia, Canada. Individuals who were receiving OAT at opioid RMG initiation and individuals who were receiving OAT and eligible but unexposed to opioid RMG were propensity score matched at opioid RMG initiation on sociodemographic and clinical variables. Data were analyzed between January 2023 and February 2024.Opioid RMG receipt (≥4 days, 1-3 days, or 0 days of opioid RMG dispensed) in a given week.The main outcome was OAT receipt, defined as at least 1 dispensed dose of OAT in the subsequent week. A marginal structural modeling approach was used to control for potential time-varying confounding.A total of 4636 individuals (2955 [64%] male; median age, 38 [31-47] years after matching) were receiving OAT at the time of first opioid RMG dispensation (2281 receiving ongoing OAT and 2352 initiating RMG and OAT concurrently). Opioid RMG receipt of 1 to 3 days in a given week increased the probability of OAT receipt by 27% in the subsequent week (adjusted risk ratio, 1.27; 95% CI, 1.25-1.30), whereas receipt of opioid RMG for 4 days or more resulted in a 46% increase in the probability of OAT receipt in the subsequent week (adjusted risk ratio, 1.46; 95% CI, 1.43-1.49) compared with those not receiving opioid RMG. The biological gradient was robust to different exposure classifications, and the association was stronger among those initiating opioid RMG and OAT concurrently.This cohort study, which acknowledged the intermittent use of both medications, demonstrated that individuals who were coprescribed opioid RMG had higher adjusted probability of continued OAT receipt or reengagement compared with those not receiving opioid RMG.
dc.description.sponsorshipThis study was funded by grant 172671 from the Canadian Institutes for Health Research, grant 18951 from the Michael Smith Foundation for Health Research, and grant R01-DA050629 from the National Institute on Drug Abuse.
dc.identifier.citationMin, J. E., Guerra-Alejos, B. C., Yan, R., Palis, H., Barker, B., Urbanoski, K., Pauly, B., Slaunwhite, A., Bach, P., Ranger, C., Heaslip, A., & Nosyk, B. (2024). Opioid coprescription through risk mitigation guidance and opioid agonist treatment receipt. JAMA Network Open, 7(5), e2411389. https://doi.org/10.1001/jamanetworkopen.2024.11389
dc.identifier.urihttps://doi.org/10.1001/jamanetworkopen.2024.11389
dc.identifier.urihttps://hdl.handle.net/1828/21656
dc.language.isoen
dc.publisherJAMA Network Open
dc.rightsCC BY 4.0
dc.rights.urihttp://creativecommons.org/licenses/by/4.0
dc.titleOpioid coprescription through risk mitigation guidance and opioid agonist treatment receipt
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
min_jeongeun_JAMANetwOpen_2024.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
Download

Collections

Faculty Publications (Human & Social Development)
 
University of Victoria Libraries

We acknowledge and respect the Lək̓ʷəŋən (Songhees and Esquimalt) Peoples on whose territory the university stands, and the Lək̓ʷəŋən and W̱SÁNEĆ Peoples whose historical relationships with the land continue to this day.